Isis Announces Positive Preliminary Results on Open-label Phase 2 Study in Patients with TTR Amyloid Cardiomyopathy

Isis Pharmaceuticals, Inc. ISIS announced today positive preliminary results from an ongoing investigator sponsored, open-label Phase 2 study in patients with TTR amyloid cardiomyopathy, which included patients with familial amyloid cardiomyopathy (FAC) and patients with wild-type transthyretin amyloidosis (wt-TTR amyloidosis, previously referred to as senile systemic amyloidosis, or SSA). In this study, patients receive one injection of ISIS-TTRRx once a week. The study will continue for 24 months. Data from patients treated for 12 months were presented today (abstract # PM14) by the lead investigator, Merrill D. Benson, M.D., at the First European Congress on Hereditary ATTR amyloidosis in Paris, France. Isis will review these data and the overall development plan for ISIS-TTRRx in a webcast scheduled for Tuesday, Nov. 3 at 8:00 a.m. Eastern Time. "Data from our study is encouraging. The study is designed to monitor progression of cardiomyopathy in patients treated with ISIS-TTRRx. The MRI data measured left ventricular mass for the first three patients to complete See full press release